ARS Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
ARS Pharmaceuticals, Inc. (SPRY) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.30% for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2025-11-10
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-03-31 was 4.40%, a 12.82% increase year-over-year.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-03-31 was 3.90%, a 0.00% change year-over-year.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-03-31 was 3.90%, a 143.75% increase year-over-year.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-03-31 was 1.60%, a 122.22% increase year-over-year.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 3.90%, a 0.00% change from fiscal 2023.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.90%, a 85.71% increase from fiscal 2022.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 2.10%, a 75.00% increase from fiscal 2021.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2021 was 1.20%, a 135.29% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 4.30% 10-Q · filed 2025-11-10 | ||||||||
| 2025-06-30 | 4.30% 10-Q · filed 2025-08-13 | ||||||||
| 2025-03-31 | 4.40% 10-Q · filed 2025-05-14 | ||||||||
| 2024-12-31 | 3.90% 10-K · filed 2025-03-20 | ||||||||
| 2024-09-30 | 3.90% 10-Q · filed 2025-11-10 | ||||||||
| 2024-06-30 | 4.00% 10-Q · filed 2025-08-13 | ||||||||
| 2024-03-31 | 3.90% 10-Q · filed 2025-05-14 | ||||||||
| 2023-12-31 | 3.90% 10-K · filed 2025-03-20 | ||||||||
| 2023-09-30 | 3.90% 10-Q · filed 2024-11-13 | ||||||||
| 2023-06-30 | 3.90% 10-Q · filed 2024-08-06 | ||||||||
| 2023-03-31 | 3.90% 10-Q · filed 2024-05-09 | ||||||||
| 2022-12-31 | 2.10% 10-K · filed 2024-03-21 | ||||||||
| 2022-11-08 | 4.50% 10-K · filed 2023-03-23 | ||||||||
| 2022-09-30 | 2.10% 10-Q · filed 2023-11-09 | 2.24% 10-Q · filed 2022-11-02 | |||||||
| 2022-06-30 | 2.10% 10-Q · filed 2023-08-10 | 2.24% 10-Q · filed 2022-08-11 | |||||||
| 2022-03-31 | 1.60% 10-Q · filed 2023-05-15 | 1.70% 10-Q · filed 2022-05-12 | |||||||
| 2021-12-31 | 1.20% 10-K · filed 2023-03-23 | 0.98% 10-K · filed 2022-03-31 | |||||||
| 2021-09-30 | 0.94% 10-Q · filed 2022-11-02 | ||||||||
| 2021-06-30 | 0.97% 10-Q · filed 2022-08-11 | ||||||||
| 2021-03-31 | 0.72% 10-Q · filed 2022-05-12 | ||||||||
| 2020-12-31 | 0.51% 10-K · filed 2022-03-31 | ||||||||
| 2020-09-30 | 0.51% 10-Q · filed 2021-11-10 | ||||||||
| 2020-06-30 | 0.51% 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |